Advertisement

Association of total VLDL particle concentrations with elevated blood viscosity in patients with type 2 diabetes

  • Robert S. Rosenson
    Correspondence
    Corresponding author at: Director of Metabolism and Lipids, Mount Sinai Health System, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Hospital Box 1030, New York, NY 10029, USA.
    Affiliations
    Metabolism and Lipids Unit, Zena and Michael A. Wiener Cardiovascular Institute, Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, One Gustav L. Levy Place, New York, NY 10029, USA
    Search for articles by this author
  • Martin L. Lee
    Affiliations
    UCLA Fielding School of Public Health, 650 Charles E. Young Drive S. 51-254 CHS, Los Angeles, CA 90095, USA
    Search for articles by this author
  • Qinzhong Chen
    Affiliations
    Metabolism and Lipids Unit, Zena and Michael A. Wiener Cardiovascular Institute, Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, One Gustav L. Levy Place, New York, NY 10029, USA
    Search for articles by this author
Published:December 16, 2021DOI:https://doi.org/10.1016/j.diabres.2021.109180

      Abstract

      Microvascular disease is an important cause of morbidity in patients with T2DM. Total VLDL concentrations is associated with increased BV, a major determinant of microvascular flow in patients with T2DM. Measurement of VLDL concentration may provide insight into lipoprotein associated microvascular complications of diabetes.
      T1DM (Type 1 diabetes mellitus), T2DM (Type 2 diabetes mellitus), BV (Blood viscosity), HTG (Hypertriglyceridemia), VLDL (Very low density lipoprotein), LDL (Low density lipoprotein)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fioretto P.
        • Dodson P.M.
        • Ziegler D.
        • Rosenson R.S.
        Residual microvascular risk in diabetes: unmet needs and future directions.
        Nat Rev Endocrinol. 2010; 6: 19-25
        • Keech A.
        • Simes R.J.
        • Barter P.
        • Best J.
        • Scott R.
        • Taskinen M.R.
        • et al.
        Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
        Lancet. 2005; 366: 1849-1861
      1. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.

        • Leonhardt H.
        • Arntz H.-R.
        • Klemens U.H.
        Studies of plasma viscosity in primary hyperlipoproteinaemia.
        Atherosclerosis. 1977; 28: 29-40
        • Seplowitz A.H.
        • Chien S.
        • Smith F.R.
        Effects of lipoproteins on plasma viscosity.
        Atherosclerosis. 1981; 38: 89-95
        • Rosenson R.S.
        • Chen Q.
        • Najera S.D.
        • Lee M.L.
        • Cho D.J.
        Ticagrelor and the prevention of microvascular complications in diabetes patients with lower extremity arterial disease; rationale and design of the Hema-Kinesis trial.
        Cardiovasc Drugs Ther. 2018; 32: 443-451
        • Rosenson R.S.
        • Chen Q.
        • Najera S.D.
        • Krishnan P.
        • Lee M.L.
        • Cho D.J.
        Ticagrelor improves blood viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: the Hema-kinesis clinical trial.
        Cardiovasc Diabetol. 2019; 18: 77
        • Liu H.
        • Cai M.
        Effect of probucol on hemodynamics, rheology and blood lipid of diabetic retinopathy.
        Exp Ther Med. 2018; 15: 3809-3814
        • Lowe G.D.
        • Lowe J.M.
        • Drummond M.M.
        • Reith S.
        • Belch J.J.
        • Kesson C.M.
        • et al.
        Blood viscosity in young male diabetics with and without retinopathy.
        Diabetologia. 1980; 18: 359-363
        • Solerte S.B.
        • Fioravanti M.
        • Cerutti N.
        • Severgnini S.
        • Locatelli M.
        • Pezza N.
        • et al.
        Retrospective analysis of long-term hemorheologic effects of pentoxifylline in diabetic patients with angiopathic complications.
        Acta Diabetol. 1997; 34: 67-74
        • Young M.J.
        • Bennett J.L.
        • Liderth S.A.
        • Veves A.
        • Boulton A.J.
        • Douglas J.T.
        Rheological and microvascular parameters in diabetic peripheral neuropathy.
        Clin Sci (Lond). 1996; 90: 183-187